Cargando…

Clinical characteristics of patients with chronic obstructive pulmonary disease assessed using GOLD 2016 and GOLD 2018 classifications: a cross-sectional study in China

BACKGROUND: In 2017, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) removed spirometry as a criterion for classifying GOLD risk groups (A–D, low–high risk). METHODS: In this cross-sectional observational study in China, we used the GOLD 2016 (spirometry included) and 2018 (spirome...

Descripción completa

Detalles Bibliográficos
Autores principales: Jian, Wenhua, Zeng, Huiqing, Zhang, Xiaoju, Yun, Chunmei, Xu, Zuojun, Chen, Yan, Shi, Guochao, Wang, Yingyu, Li, Yun, Zheng, Jinping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575805/
https://www.ncbi.nlm.nih.gov/pubmed/34795920
http://dx.doi.org/10.21037/jtd-21-255
_version_ 1784595748374970368
author Jian, Wenhua
Zeng, Huiqing
Zhang, Xiaoju
Yun, Chunmei
Xu, Zuojun
Chen, Yan
Shi, Guochao
Wang, Yingyu
Li, Yun
Zheng, Jinping
author_facet Jian, Wenhua
Zeng, Huiqing
Zhang, Xiaoju
Yun, Chunmei
Xu, Zuojun
Chen, Yan
Shi, Guochao
Wang, Yingyu
Li, Yun
Zheng, Jinping
author_sort Jian, Wenhua
collection PubMed
description BACKGROUND: In 2017, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) removed spirometry as a criterion for classifying GOLD risk groups (A–D, low–high risk). METHODS: In this cross-sectional observational study in China, we used the GOLD 2016 (spirometry included) and 2018 (spirometry eliminated) criteria for classifying GOLD risk groups to describe: the proportion of patients with chronic obstructive pulmonary disease (COPD) in each GOLD risk group; disease severity; demographics and comorbidities. Patients aged ≥40 years with a clinical COPD diagnosis for ≥1 year were included. During a single study visit, patients completed the COPD assessment test, modified Medical Research Council (mMRC) dyspnea scale assessment, and spirometry tests. Demographics, medical history, and treatment data were recorded. RESULTS: In total, 838 patients were included. Most patients were male (86.4%), ≥65 years old (58.6%), and current or former smokers (78.5%). By GOLD 2016, the highest proportion of patients were Group D (42.8%), followed by B (28.2%). By GOLD 2018, the highest proportion of patients were Group B (57.3%), followed by A (25.5%). A total of 296 patients (35.3%) were reclassified, either from Group C to Group A or from Group D to Group B. Overall, 36.2% of patients were receiving treatment concordant with GOLD 2016 recommendations; 34.1% were not receiving any inhaled medication. CONCLUSIONS: The distribution of COPD severity shifted from a high-risk category (by GOLD 2016) to a low-risk category (by GOLD 2018). The high proportion of patients not receiving maintenance medication reflects a high level of under-treatment of the disease.
format Online
Article
Text
id pubmed-8575805
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-85758052021-11-17 Clinical characteristics of patients with chronic obstructive pulmonary disease assessed using GOLD 2016 and GOLD 2018 classifications: a cross-sectional study in China Jian, Wenhua Zeng, Huiqing Zhang, Xiaoju Yun, Chunmei Xu, Zuojun Chen, Yan Shi, Guochao Wang, Yingyu Li, Yun Zheng, Jinping J Thorac Dis Original Article BACKGROUND: In 2017, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) removed spirometry as a criterion for classifying GOLD risk groups (A–D, low–high risk). METHODS: In this cross-sectional observational study in China, we used the GOLD 2016 (spirometry included) and 2018 (spirometry eliminated) criteria for classifying GOLD risk groups to describe: the proportion of patients with chronic obstructive pulmonary disease (COPD) in each GOLD risk group; disease severity; demographics and comorbidities. Patients aged ≥40 years with a clinical COPD diagnosis for ≥1 year were included. During a single study visit, patients completed the COPD assessment test, modified Medical Research Council (mMRC) dyspnea scale assessment, and spirometry tests. Demographics, medical history, and treatment data were recorded. RESULTS: In total, 838 patients were included. Most patients were male (86.4%), ≥65 years old (58.6%), and current or former smokers (78.5%). By GOLD 2016, the highest proportion of patients were Group D (42.8%), followed by B (28.2%). By GOLD 2018, the highest proportion of patients were Group B (57.3%), followed by A (25.5%). A total of 296 patients (35.3%) were reclassified, either from Group C to Group A or from Group D to Group B. Overall, 36.2% of patients were receiving treatment concordant with GOLD 2016 recommendations; 34.1% were not receiving any inhaled medication. CONCLUSIONS: The distribution of COPD severity shifted from a high-risk category (by GOLD 2016) to a low-risk category (by GOLD 2018). The high proportion of patients not receiving maintenance medication reflects a high level of under-treatment of the disease. AME Publishing Company 2021-10 /pmc/articles/PMC8575805/ /pubmed/34795920 http://dx.doi.org/10.21037/jtd-21-255 Text en 2021 Journal of Thoracic Disease. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Jian, Wenhua
Zeng, Huiqing
Zhang, Xiaoju
Yun, Chunmei
Xu, Zuojun
Chen, Yan
Shi, Guochao
Wang, Yingyu
Li, Yun
Zheng, Jinping
Clinical characteristics of patients with chronic obstructive pulmonary disease assessed using GOLD 2016 and GOLD 2018 classifications: a cross-sectional study in China
title Clinical characteristics of patients with chronic obstructive pulmonary disease assessed using GOLD 2016 and GOLD 2018 classifications: a cross-sectional study in China
title_full Clinical characteristics of patients with chronic obstructive pulmonary disease assessed using GOLD 2016 and GOLD 2018 classifications: a cross-sectional study in China
title_fullStr Clinical characteristics of patients with chronic obstructive pulmonary disease assessed using GOLD 2016 and GOLD 2018 classifications: a cross-sectional study in China
title_full_unstemmed Clinical characteristics of patients with chronic obstructive pulmonary disease assessed using GOLD 2016 and GOLD 2018 classifications: a cross-sectional study in China
title_short Clinical characteristics of patients with chronic obstructive pulmonary disease assessed using GOLD 2016 and GOLD 2018 classifications: a cross-sectional study in China
title_sort clinical characteristics of patients with chronic obstructive pulmonary disease assessed using gold 2016 and gold 2018 classifications: a cross-sectional study in china
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575805/
https://www.ncbi.nlm.nih.gov/pubmed/34795920
http://dx.doi.org/10.21037/jtd-21-255
work_keys_str_mv AT jianwenhua clinicalcharacteristicsofpatientswithchronicobstructivepulmonarydiseaseassessedusinggold2016andgold2018classificationsacrosssectionalstudyinchina
AT zenghuiqing clinicalcharacteristicsofpatientswithchronicobstructivepulmonarydiseaseassessedusinggold2016andgold2018classificationsacrosssectionalstudyinchina
AT zhangxiaoju clinicalcharacteristicsofpatientswithchronicobstructivepulmonarydiseaseassessedusinggold2016andgold2018classificationsacrosssectionalstudyinchina
AT yunchunmei clinicalcharacteristicsofpatientswithchronicobstructivepulmonarydiseaseassessedusinggold2016andgold2018classificationsacrosssectionalstudyinchina
AT xuzuojun clinicalcharacteristicsofpatientswithchronicobstructivepulmonarydiseaseassessedusinggold2016andgold2018classificationsacrosssectionalstudyinchina
AT chenyan clinicalcharacteristicsofpatientswithchronicobstructivepulmonarydiseaseassessedusinggold2016andgold2018classificationsacrosssectionalstudyinchina
AT shiguochao clinicalcharacteristicsofpatientswithchronicobstructivepulmonarydiseaseassessedusinggold2016andgold2018classificationsacrosssectionalstudyinchina
AT wangyingyu clinicalcharacteristicsofpatientswithchronicobstructivepulmonarydiseaseassessedusinggold2016andgold2018classificationsacrosssectionalstudyinchina
AT liyun clinicalcharacteristicsofpatientswithchronicobstructivepulmonarydiseaseassessedusinggold2016andgold2018classificationsacrosssectionalstudyinchina
AT zhengjinping clinicalcharacteristicsofpatientswithchronicobstructivepulmonarydiseaseassessedusinggold2016andgold2018classificationsacrosssectionalstudyinchina